Channing Judith Paller, M.D.

Headshot of Channing Judith Paller
  • Director, Prostate Cancer Clinical Research
  • Associate Professor of Oncology
Female

Expertise

Bladder Cancer, Kidney Cancer, Medical Oncology, Prostate Cancer, Testicular Cancer, Urological Oncology ...read more

Research Interests

TGF-beta receptor inhibitor and tumor microenvironment; natural products including mistletoe, pomegranate, vitamin C, vitamin D, and muscadine grape skin extract; aurora kinase inhibition; phase I combination drug trial design ...read more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment

Locations

Sibley Memorial Hospital

Appointment Phone: 202-660-6500
5255 Loughboro Road, NW
1st Floor
Washington, DC 20016
Fax: 202-660-6501
Sibley Memorial Hospital - Google Maps

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231
Fax: 410-955-8587
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Google Maps

Background

Dr. Channing J. Paller is a medical oncologist at Sibley Memorial Hospital and an associate professor of oncology at the Johns Hopkins University School of Medicine. She practices out of the Prostate Cancer Multidisciplinary Clinic at Sibley Memorial Hospital in Washington, D.C., and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, MD.

Dr. Paller has expertise in prostate, bladder, kidney, and testicular cancer.

Dr. Paller earned her medical degree from Harvard Medical School and completed a residency in internal medicine, followed by a fellowship in hematology and oncology at Johns Hopkins University School of Medicine. In addition, Dr. Paller completed a rotation with the chief of the Investigational Drug Branch at the National Cancer Institute (NCI) Cancer Therapy Evaluation Program and a rotation with the associate director for regulatory science in the Office of Oncology Drug Products at the Food and Drug Administration. She also completed rotations at the Weizmann Institute of Israel’s Department of Biological Regulation and McCord Hospital in South Africa, where she participated in the Harvard AIDS project.

In 2016, Dr. Paller was one of only five oncologists awarded the NCI Mentored Patient-Oriented Research Career Development Award. In 2015, she received the 2015 Passano Clinician Scientist Award for early-stage research that is already making a contribution to science. Earlier in her career, she was selected for both a 2011-2012 Young Investigator Award by the American Society of Clinical Oncology and for the 2011-12 Eastern Cooperative Oncology Group Paul Carbone Award.

Dr. Paller is a member of the American Society of Clinical Oncology and the American Association for Cancer Research. 

Dr. Paller’s research focuses on evaluating new therapies for prostate cancer, particularly combination therapies that engage the immune system. She is the principal investigator on two multi-site clinical trials and was the first author on the NCI Investigational Drug Steering Committee publication, “Consensus Recommendations on the Phase I Combination Clinical Trials of the Clinical Trial Design Task Force.” Dr. Paller was the chair for the oral abstract session on genitourinary cancer at the 2015 Annual Meeting of the American Society of Clinical Oncology and she is currently funded by an NCI immunotherapy grant to look at combination therapies that link standard of care therapy with inhibition of transforming growth factor beta in prostate cancer. She is also opening trials of vitamin C with chemotherapy in prostate cancer and of mistletoe in all solid tumors.

...read more

Titles

  • Director, Prostate Cancer Clinical Research
  • Associate Director of Oncology, Johns Hopkins Clinical Research Network
  • Associate Professor of Oncology
  • Associate Professor of Urology

Departments / Divisions

  • Medicine at Sibley Memorial Hospital
  • Oncology - Genitourinary Cancer Disease
  • Urology

Centers & Institutes

Education

Degrees

  • MD; Harvard Medical School (2005)

Residencies

  • Medicine; Johns Hopkins University School of Medicine (2008)

Fellowships

  • Hematology and Oncology; Johns Hopkins University School of Medicine (2012)

Board Certifications

  • American Board of Internal Medicine (Internal Medicine) (2008)
  • American Board of Internal Medicine (Medical Oncology) (2010)

Research & Publications

Research Summary

Dr. Paller’s research focuses on evaluating new therapies for prostate cancer, particularly combination therapies that engage the immune system.

Clinical Trials

Dr. Paller is the principal investigator on multi-site clinical trials and was the first author on the NCI Investigational Drug Steering Committee publication, “Consensus Recommendations on the Phase I Combination Clinical Trials of the Clinical Trial Design Task Force.”

Selected Publications

View all on PubMed

Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, Stockton BR, Hertzman BL, Efros MD, Roper RP, Liker HR, Carducci MA. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis. 2013 Mar;16(1):50-5. doi: 10.1038/pcan.2012.20. Epub 2012 Jun 12. PMCID: PMC3549301.

Paller CJ, Olatoye D, Xie S, Zhou X, Denmeade SR, Eisenberger MA, Antonarakis ES, Carducci MA, Rosner GL. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2014 Mar;17(1):28-33. doi: 10.1038/pcan.2013.40. Epub 2013 Oct 8. PMCID: PMC3945997.

Paller, C., Bradbury, P.A., Ivy, P., Seymour, L., LoRusso, P., Baker, L., Rubinstein, L., Huang, E., Collyar, D., Groshen, S., Reeves, S., Ellis, L.M., Sargent, D., Rosner, G.L., LeBlanc, M., Ratain, M.J. The Design of Phase 1 Combination Trials: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clinical Cancer Research. 2014, 20(16): 4210–4217. PMCID: PMC4135521.

Paller CJ, Kanaan YM, Beyene DA, Naab TJ, Copeland RL, Tsai HL, Kanarek NF, Hudson TS. Risk of Prostate Cancer in African American Men: Evidence of Mixed Effects of Dietary Quercetin by Serum Vitamin D Status. Prostate. 2015 Sep;75(13):1376-83. PMCID: NIHMS689470.

Contact for Research Inquiries

The Skip Viragh Outpatient Cancer Building
201 North Broadway, Suite 9123
Baltimore, MD 21287 map
Phone: 410-955-8239
Fax: 202-660-6501

Activities & Honors

Honors

  • Passano Clinician Scientist Award, 2015
  • Young Investigator Award, American Society of Clinical Oncology, 2011 - 2012
  • Paul Carbone Award, Eastern Cooperative Oncology Group, 2011 - 2012
  • NCI Mentored Patient-Oriented Research Career Development Award, National Cancer Institute, 2016

Memberships

  • American Society of Clinical Oncology (ASCO)

    2015 Chair for the Oral Abstract Session on Genitourinary Cancer at ASCO's Annual Meeting

  • American Association for Cancer Research

Videos & Media

Recent News Articles and Media Coverage

Some D.C. Doctors Are Tackling Cancer Cures in a Surprisingly Low-Tech Way. Washington Business Journal (09/29/2016)

Isn’t It Time We Acknowledged the Potential of Immunotherapy? The Telegraph (05/26/2015)

Is this you? Edit Profile
back to top button